INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX
Pomerantz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NNOX) following a significant drop in its stock price. The investigation stems from Nano-X's Q4 2025 financial results, which reported a $33.4 million net loss due to a $17.5 million impairment charge at its Korean chip manufacturing facility and the announced departure of its CFO. Consequently, Nano-X's stock fell 24.39% on April 20, 2026.
Law firm investigates Nano-X Imaging for possible securities fraud after Q4 loss and CFO resignation news.
Pomerantz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. following the company's report of a significant $33.4 million net loss in Q4 2025, largely due to a $17.5 million impairment charge related to restructuring its Korean chip facility. The investigation also stems from the resignation of CFO Ran Daniel. After these announcements, Nano-X's stock price experienced a substantial 24.39% drop, raising concerns among investors.
[SCHEDULE 13G/A] Nano-X Imaging Ltd. Amended Passive Investment Disclosure
Nano-X Imaging Ltd. has reported an amended passive investment disclosure (Schedule 13G/A), indicating that SK square Co., Ltd. and SK Square Americas, Inc. are no longer beneficial owners of over 5% of its ordinary shares. This "exit filing" updates a previous Schedule 13G from February 2022, with the reporting persons now holding 0.0% ownership as of the March 31, 2026 cover date.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nano-X Imaging Ltd. (NNOX) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nano-X Imaging Ltd. (NNOX) after the company reported a net loss due to a $17.5 million impairment charge and the CFO announced their departure. Following this news, Nano-X's stock price dropped by 25%. The firm is encouraging shareholders who purchased Nano-X securities to connect for additional information and to assist the investigation.
Nano-X Imaging (NNOX) Builds Commercial Momentum With Multi-Year Nanox.ARC Deployment Deals
Nano-X Imaging Ltd. (NNOX) is gaining commercial momentum with new multi-year deployment deals for its Nanox.ARC medical imaging systems. The company recently signed a U.S. distribution agreement with NuvioDx LLC and previously partnered with Howard Technology Solutions to install 300 Nanox.ARC systems. These agreements reinforce Nano-X Imaging's channel-led growth strategy and contribute to its forecast of $35 million in earnings for 2026.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nano-X Imaging Ltd. (NNOX) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nano-X Imaging Ltd. (NNOX) following a 25% drop in its stock price after the company announced a significant net loss due to a $17.5 million impairment charge and the CFO's departure. The firm encourages investors who purchased Nano-X securities to join the investigation, which seeks to recover investor capital on a contingency fee basis. Investors can find more information on the firm's website or by contacting Peretz Bronstein or Nathan Miller.
9 Most Popular AI Penny Stocks to Buy Under $2
This article identifies nine popular AI penny stocks under $2, focusing on Nano-X Imaging Ltd. (NASDAQ: NNOX) as an example. Nano-X Imaging is leveraging distribution and deployment partnerships to expand the reach of its FDA-cleared Nanox.ARC medical imaging systems, which offer lower-cost 3D imaging with reduced radiation. The company has agreements for significant deployments, with management forecasting $35 million in earnings for 2026, driven by its channel-led growth strategy.
Nano-X Imaging Ltd. (NNOX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nano-X Imaging Ltd. (NNOX) following a significant 25% stock drop. This decline occurred after the company reported a Q4 2025 net loss, including a $17.5 million impairment charge for its Korean chip manufacturing facility, and announced the CFO's resignation. Shareholders who purchased Nano-X securities are encouraged to contact the firm to learn more and potentially assist with the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX
Pomerantz LLP has launched an investigation into Nano-X Imaging Ltd. (NASDAQ: NNOX) following an announcement of its Q4 2025 financial results, which included a significant net loss and an impairment charge related to a restructuring at its Korean chip manufacturing facility. The investigation, prompted by a 24.39% drop in Nano-X's stock price, concerns potential securities fraud by the company's officers and/or directors. Pomerantz is urging affected investors to come forward and contact the firm.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nano-X Imaging Ltd. (NNOX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nano-X Imaging Ltd. (NNOX) following a 25% stock price drop. This decline occurred after Nano-X announced a net loss due to a $17.5 million impairment charge and the CFO's resignation. The law firm encourages affected investors to contact them for more information regarding the investigation.
NNOX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Nano-X Imaging Ltd.
Kirby McInerney LLP is investigating potential claims against Nano-X Imaging Ltd. (NASDAQ: NNOX) on behalf of its investors. This investigation follows a significant drop in Nano-X's share price after the company reported a net loss of $33.4 million for Q4 2025, partly due to an impairment charge, and announced the stepping down of its CFO. The firm is looking into possible violations of federal securities laws and unlawful business practices.
Wolf Haldenstein Adler Freeman & Herz LLP is investigating
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NASDAQ: NNOX) on behalf of its shareholders. This investigation follows Nano-X's announcement of a $33.4 million net loss in Q4 2025, primarily due to an asset impairment charge, and the stepping down of its CFO, which caused a significant drop in the company's stock price. The firm is encouraging affected investors to contact them for a discussion regarding their rights and interests.
Wolf Haldenstein Adler Freeman & Herz LLP is investigating
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NASDAQ: NNOX) following an announcement of a Q4 2025 net loss of $33.4 million, including a significant impairment charge, and the stepping down of its CFO. The investigation comes after Nano-X's stock price fell by 24.39% following these disclosures. The law firm is seeking to connect with affected shareholders.
Wolf Haldenstein Adler Freeman & Herz LLP is investigating
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Nano-X Imaging Ltd. (NASDAQ: NNOX) for potential securities fraud. This investigation follows Nano-X's Q4 2025 financial results, which reported a net loss of $33.4 million, including a significant impairment charge, and the announcement of their CFO's resignation. Nano-X's stock price subsequently fell by 24.39%.
Nanox adds U.S. distributor for lower-radiation 3D imaging
Nano X Imaging (NNOX) has signed a distribution agreement with NuvioDx to deploy its FDA-cleared Nanox.ARC systems across multiple U.S. states. The Nanox.ARC is a multisource digital tomosynthesis system designed for lower-cost, reduced-radiation 3D imaging compared to traditional CT. This partnership strengthens Nanox's commercialization strategy and expands its U.S. distribution network.
Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
Nanox has signed a distribution agreement with NuvioDx LLC to advance the deployment of its Nanox.ARC multi-source digital tomosynthesis systems across various U.S. clinical sites. This partnership is part of Nanox's strategy to expand its distribution network and increase access to its innovative medical imaging technology, which offers 3D imaging at a lower cost and reduced radiation dose. NuvioDx will leverage its expertise to support market adoption and sustained utilization of the Nanox.ARC systems.
Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
Nanox has signed a distribution agreement with NuvioDx LLC to deploy its Nanox.ARC multi-source digital tomosynthesis systems across various clinical sites in the U.S. This partnership aims to strengthen Nanox's commercialization strategy and expand access to its FDA-cleared 3D imaging technology, which offers lower cost and reduced radiation dosage compared to traditional CT scans. NuvioDx will utilize its regional market access and operational capabilities to support system deployment and utilization, advancing Nanox's goal of broadening diagnostic imaging accessibility.
Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
Nanox has signed a distribution agreement with NuvioDx LLC to deploy its Nanox.ARC multi-source digital tomosynthesis systems across various clinical sites in the U.S. This collaboration aims to strengthen Nanox's commercialization strategy and expand access to its FDA-cleared 3D imaging technology, which offers lower cost and reduced radiation exposure compared to traditional CT scans. NuvioDx will utilize its regional market access and operational capabilities to support the adoption of Nanox's innovative medical imaging solutions, aligning with Nanox's goal of enhancing patient care and improving outcomes.
Nano-X Imaging (NNOX) price target decreased by 10.14% to 6.78
Nano-X Imaging (NNOX) has seen its price target decreased by 10.14%, bringing it down to $6.78. This adjustment reflects a updated valuation of the company's stock by analysts.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX
Pomerantz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NNOX) on behalf of investors. This investigation follows a significant drop in Nano-X's stock price after the company reported a net loss of $33.4 million for Q4 2025, largely due to an asset impairment charge from a restructuring initiative, and announced its CFO would step down. Investors are encouraged to contact the law firm for more information regarding joining a potential class action.
Nano-X Imaging (NNOX) director Suesskind reports RSUs and stock options
Nano-X Imaging Ltd. director Dan S. Suesskind has filed a Form 3, detailing his initial equity holdings in the company. The filing shows he holds ordinary shares underlying Restricted Share Units (RSUs) from grants in 2024 and 2025, which vest quarterly over several years. Additionally, Suesskind possesses fully vested stock options and other options with various exercise prices that will vest in quarterly installments.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nano-X Imaging Ltd. (NNOX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nano-X Imaging Ltd. (NNOX) after the Company reported a significant net loss and an impairment charge in Q4 2025, leading to a 25% drop in stock price. The investigation encourages stockholders affected by these events to contact the firm for assistance. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Nano-X Imaging (Nasdaq:NNOX) - Stock Analysis
This Simply Wall Street analysis of Nano-X Imaging Ltd. (NNOX) provides an overview of the company's financial health, future growth potential, and recent performance. While the company is currently unprofitable, analysts forecast significant revenue growth and have recently revised price targets based on updated assumptions regarding discount rates, revenue growth, and profit margins. Recent news highlights new distribution agreements and FDA clearances that are expected to support future deployment and growth.
Nano-X Imaging Ltd. (NNOX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nano-X Imaging Ltd. (NNOX) following a significant drop in its stock price. The investigation was initiated after Nano-X announced its Q4 2025 financial results, which included a $17.5 million impairment charge and the CFO's impending departure, leading to a 25% stock decline. The firm encourages affected stockholders to contact them to learn more about the ongoing class action investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nano-X Imaging Ltd. (NNOX) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nano-X Imaging Ltd. (NNOX) following a significant 25% stock price drop when the company announced a Q4 2025 net loss of $17.5 million due to an impairment charge and the stepping down of its CFO. The firm is encouraging investors who purchased Nano-X securities to join the investigation, offering representation on a contingency fee basis. This aims to restore investor capital and ensure corporate accountability.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX
Pomerantz LLP is investigating Nano-X Imaging Ltd. (NASDAQ: NNOX) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Nano-X's Q4 2025 financial results, which reported a $33.4 million net loss and a significant stock price drop after the announcement of an impairment charge and CFO's departure. Investors affected by the stock's decline are encouraged to contact the law firm.
NNOX Investors Have Opportunity to Join Nano-X Imaging Ltd. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Nano-X Imaging Ltd. (NNOX) on behalf of investors for potential securities law violations. This investigation follows a Q4 2025 net loss announcement, primarily due to a $17.5 million impairment charge on its Korean chip manufacturing facility, and the CFO's impending departure, which caused the company's shares to fall by 25%. Investors who suffered losses are encouraged to contact the law firm to discuss their rights.
NANO-X IMAGING launches $15M stock offering
The article reports that NANO-X IMAGING has launched a $15 million stock offering. This information suggests a capital-raising initiative by the company.
Nanox (NNOX) posts $75M 2025 loss, targets $35M 2026 revenue after restructuring
Nano-X Imaging (NNOX) reported a Q4 2025 net loss of $33.4 million on $3.7 million revenue, with a full-year 2025 net loss of $75.0 million on $13.0 million revenue. The significant loss in Q4 was largely due to a $17.5 million non-cash impairment charge from restructuring its Korean chip manufacturing operations. The company is shifting to an outsourced manufacturing model and targets $35 million in revenue for 2026, with an emphasis on deploying its Nanox.ARC systems and converting contracted opportunities into revenue-generating installations, despite current low revenue from deployed systems.
Nano-X Imaging (NNOX) Is Down 36.7% After 2025 Losses Deepen And New CFO Joins - Has The Bull Case Changed?
Nano-X Imaging (NNOX) saw a 36.7% stock drop after widening net losses to US$75.02 million for full-year 2025 and reporting a US$33.37 million net loss in Q4 2025, including a significant impairment. The company also appointed a new CFO, Guy Nathanzon, and initiated a clinical collaboration with Meir Medical Center to validate its Nanox.ARC system. These developments emphasize the continued financial pressures and the critical need for successful commercialization through real-world clinical validation, as the investment narrative remains focused on transitioning from regulatory wins to broad, revenue-generating deployments.
NANO-X INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Nano-X Imaging Ltd. on Behalf of Nano-X Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Nano-X Imaging Ltd. (NASDAQ:NNOX) on behalf of its stockholders. The investigation follows a significant net loss reported by Nano-X for Q4 2025, partly due to asset impairment, and the announcement of their CFO's resignation, which led to a 25% drop in stock price. The firm is encouraging investors who suffered losses to contact them to discuss their legal options regarding potential federal securities law violations or unlawful business practices.
Nanox signs U.S. distribution deal with Radiology Oncology Systems
Nanox, through its U.S. subsidiary Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems for its Nanox.ARC systems across the United States. This partnership aims to commercialize the FDA-cleared multisource digital tomosynthesis system, which offers 3D imaging with lower cost and reduced radiation compared to traditional CT scans. The deal expands Nanox's U.S. commercial footprint and leverages Radiology Oncology Systems' established network for deployment in clinical settings, including oncology-adjacent care.
Nanox adds U.S. distributor for lower-dose 3D imaging systems
Nanox (NASDAQ: NNOX) announced a U.S. distribution agreement with Radiology Oncology Systems to expand the adoption of its FDA-cleared Nanox.ARC system. This collaboration aims to provide wider access to lower-dose and more cost-effective 3D imaging solutions across U.S. clinical settings, particularly in oncology-adjacent environments. The agreement is part of Nanox's ongoing strategy to strengthen its U.S. commercial footprint and leverage established distribution networks.
Nanox Signs Distribution Agreement with Radiology Oncology Systems to Expand Nanox.ARC Adoption in the United States
Nano-X Imaging Ltd. (Nanox) has signed a distribution agreement with Radiology Oncology Systems (ROS) to expand the adoption of its Nanox.ARC systems across the U.S. The Nanox.ARC is an FDA-cleared digital tomosynthesis system for 3D imaging, offering lower cost and reduced radiation compared to traditional CT. This collaboration aims to broaden access to advanced imaging solutions, particularly in oncology-adjacent care environments, leveraging ROS's established network and service infrastructure for deployment.
NANO-X IMAGING LTD. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has initiated an investigation into Nano-X Imaging Ltd. (NASDAQ:NNOX) following a significant drop in stock price. The investigation concerns potential violations of federal securities laws after Nano-X reported a $33.4 million net loss for Q4 2025, largely due to a $17.5 million impairment charge, and announced the CFO's departure. Shareholders who purchased Nano-X securities are encouraged to contact the law firm for more information regarding their potential claims.
NANO-X IMAGING LTD. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NASDAQ:NNOX) following the company's Q4 2025 financial results. Nano-X reported a significant net loss and an impairment charge, leading to a 25% drop in stock price. The investigation is ongoing to determine if federal securities laws were violated, and the firm is encouraging affected investors to come forward.
Nano-X Imaging Balances Growth Hopes With Deepening Losses
Nano-X Imaging (NNOX) reported widening losses in Q4 2025 despite expanding commercial agreements and regulatory wins. The company is balancing optimism from distribution deals, strategic acquisitions, and technology advancements with challenges from weak hardware economics and the slow conversion of its pipeline into sustainable revenue. Nanox aims for a significant revenue ramp in the second half of 2026, driven by channel activation and benefits from key restructuring efforts and an equity raise.
Nano-X Imaging Ltd. (NASDAQ:NNOX) Q4 2025 Earnings Call Transcript
Nano-X Imaging Ltd. (NASDAQ:NNOX) reported its Q4 2025 earnings, missing EPS expectations with $-0.5 compared to an anticipated $-0.23. The company is actively expanding its commercial presence, particularly in the U.S. and Europe, through multiple distribution agreements for its Nanox.ARC system and strengthening its AI and Health IT businesses. Erez Meltzer, CEO, outlined strategic shifts including outsourcing manufacturing to reduce costs and focusing on long-term growth by converting system placements into revenue, while Ran Daniel, CFO, detailed a GAAP net loss of $33.4 million, influenced by a $17.5 million impairment charge from restructuring its Korean manufacturing facility.
Nano-X Imaging Balances Growth Hopes With Deepening Losses
Nano-X Imaging Ltd. (NNOX) held its Q4 earnings call, revealing a mixed picture of expanding commercial agreements and regulatory wins alongside deepening financial losses. While teleradiology drove modest revenue growth and the company made strides in health IT and regulatory clearances, significant GAAP losses were reported, largely due to asset impairment and negative hardware economics. Management reiterated a $35 million revenue target for fiscal 2026, contingent on the successful activation of distribution channels and the benefits of a manufacturing restructuring.
Nano-X Imaging Blows Past Q4 2025 Forecasts: vs -$0.20 Expected
Nano-X Imaging Ltd. (NNOX) reported a Q4 2025 non-GAAP loss per share of $0.17, which was narrower than the Wall Street estimate of a $0.20 loss. The company's revenue for the quarter reached $3.7 million, a 24.0% increase year-over-year, driven by the deployment of 36 Nanox.ARC digital X-ray systems. Despite ongoing investments leading to a net loss of $11.2 million, analysts maintain an optimistic outlook for the company's long-term potential in democratizing medical imaging.
Nano-X Imaging Narrows Q4 2025 Loss by 15.0%, Beating Estimates
Nano-X Imaging Ltd. (NNOX) reported a Q4 2025 non-GAAP loss per share of $0.17, beating analyst estimates by 15.0%, and revenue of $3.7M, an increase of 24.0% year-over-year. The company deployed 36 Nanox.ARC systems, bringing its total to 36 and showing progress in its commercialization strategy. While Nano-X Imaging remains in early-stage commercialization with a net loss of $11.2M, the narrower loss and management's full-year 2026 revenue guidance of $35.0M fueled a 5.2% stock rally, indicating investor confidence in its path to profitability.
Transcript: Nano X Imaging Q4 2025 Earnings Conference Call - Nano X Imaging (NASDAQ:NNOX)
Nano X Imaging reported a GAAP net loss of $33.4 million for Q4 2025, largely due to an impairment of long-lived assets and increased sales and marketing expenses. The company signed agreements to deploy 300 Nanox ARC systems over three years with Howard Technology Solutions and additional agreements for 360 systems across multiple markets. Revenue targets for 2026 are set at $35 million, with significant growth expected in the second half of the year as deployment and commercial agreements mature.
Nano-X Imaging Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025
Nano-X Imaging Ltd. reported its financial results for the fourth quarter and full year ended December 31, 2025. For Q4 2025, the company had sales of $3.72 million and a net loss of $33.37 million. The full year saw sales of $13.02 million and a net loss of $75.02 million.
Nano-X Imaging Posts Wider Q4 Loss but Accelerates U.S. Rollout and CFO Transition
Nano-X Imaging (NNOX) reported increased Q4 2025 revenue of $3.7 million but a wider net loss of $33.4 million, primarily due to a $17.5 million asset impairment from restructuring its South Korean manufacturing operations. Despite this, the company is accelerating the U.S. rollout of its Nanox.ARC systems through distribution deals and clinical collaborations and is preparing for a CFO transition in mid-2026. An AI analyst rates NNOX as Neutral due to weak financial performance, despite some positive expansion initiatives.
Lower-dose 3D imaging deal targets 300 U.S. deployments in 3 years
Nano-X Imaging (NASDAQ:NNOX) has signed a commercial agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems across the U.S. over three years, including 60 in the first year. The Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system offering 3D imaging at lower cost and reduced radiation. This partnership leverages Howard's national healthcare and public sector channels to broaden Nanox's market reach.
CapEx per share of NANO-X IMAGING LTD – NASDAQ:NNOX
This page from TradingView displays the "CapEx per share" financial metric for NANO-X IMAGING LTD (NASDAQ: NNOX). It shows a table with Period, Value, Change, and Change % columns, although the table itself is empty in the provided content. The article is primarily a stub for financial data related to NANO-X IMAGING.
Nano-X Imaging (NNOX) Set to Report Q4 Earnings with Positive Gr
Nano-X Imaging (NNOX) is poised to release its Q4 earnings on April 20th. Analysts are anticipating year-over-year increases of 34.8% in EPS to -$0.15 and 33.0% in revenue to $3.99 million. The company's GF Score™ of 46/100, combined with its 6/10 financial strength rating, suggests moderate performance and some financial stability, though profitability and growth remain areas of concern for investors.
Nanox.ARC X Digital Advanced 3D imaging built for access
Nanox Imaging Ltd. has been awarded a Red Dot Award: Product Design 2026 for its Nanox.ARC X 3D digital tomosynthesis system, recognized for its exceptional product design that expands access to advanced imaging. The system utilizes proprietary digital Nanox.SOURCE X-ray technology and advanced tomosynthesis in a compact, integrated unit, facilitating deployment in various clinical settings. This award underscores Nanox's mission to enhance medical imaging accessibility and improve patient outcomes through innovative design and technology.
Nanox's compact 3D imaging system for more care settings wins Red Dot
Nanox (Nasdaq: NNOX) announced that its Nanox.ARC X 3D digital tomosynthesis system has won the Red Dot Award: Product Design 2026. The award recognizes the system's compact, single-unit design, plug-and-play installation, simplified workflow, and capability for broader clinical deployment in various healthcare settings. This recognition increases global visibility for the system, which offers a significantly reduced physical footprint compared to traditional CT systems, supporting Nanox's mission to expand access to medical imaging.
Nanox.ARC X Digital Advanced 3D imaging built for access
Nanox Imaging Ltd. has received a Red Dot Award: Product Design 2026 for its Nanox.ARC X 3D digital tomosynthesis system, recognizing its design excellence in expanding access to advanced imaging. The system utilizes proprietary digital Nanox.SOURCE X-ray technology and tomosynthesis, making it compact and suitable for various clinical environments. This award highlights Nanox's mission to improve patient outcomes through accessible medical imaging.
